Unicycive Therapeutics (UNCY) Other Working Capital Changes (2022 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Other Working Capital Changes came in at -$211000.0 in Q1 2026, down 58.65% YoY from -$510236.4 in Q1 2025, and down 42.57% on a QoQ basis from -$148000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 5 years of Other Working Capital Changes data on file, last reported at -$211000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 58.65% year-over-year to -$211000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$643000.0 (down 150.19% YoY) and the FY2025 annual result came in at -$565000.0, down 42.32% from the prior year.
- Other Working Capital Changes eased to -$211000.0 in Q1 2026, from -$148000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $3.4 million in Q3 2024 to a low of -$1.3 million in Q1 2024.
- A 5-year average of $354470.6 and a median of $98000.0 in 2025 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 316.98% in 2024, down 405.56% in 2024.
- Tracing UNCY's Other Working Capital Changes over 5 years: stood at -$40000.0 in 2022, then sank by 82.5% to -$73000.0 in 2023, then sank by 72.6% to -$126000.0 in 2024, then declined by 17.46% to -$148000.0 in 2025, then slumped by 42.57% to -$211000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$211000.0 (Q1 2026), -$148000.0 (Q4 2025), and -$144000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -144,000.00 |
| Jun 30, 2026 | -144,000.00 |
| Jun 30, 2026 | -144,000.00 |
| Mar 31, 2026 | -211,000.00 |
| Mar 31, 2026 | -211,000.00 |
| Mar 31, 2026 | -211,000.00 |
| Dec 31, 2025 | -148,000.00 |
| Dec 31, 2025 | -148,000.00 |
| Dec 31, 2025 | -148,000.00 |
| Sep 30, 2025 | -144,000.00 |
| Sep 30, 2025 | -144,000.00 |
| Sep 30, 2025 | -144,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Mar 31, 2025 | -133,000.00 |
| Mar 31, 2025 | -133,000.00 |
| Mar 31, 2025 | -133,000.00 |
| Dec 31, 2024 | -126,000.00 |
| Dec 31, 2024 | -126,000.00 |